Ten years ago, Big Pharma was the golden child of Wall Street. That was before the Obama-era regulations started to pile up.

Last night, Novo Nordisk reported a major financial setback with their stock price taking a nosedive. It's not just about this one company. This is the story of how Democrat policies strangle innovation and growth in our country.

Their CEO, in an interview last week, didn't mince words: 'We are facing unprecedented challenges due to reduced drug prices and increased competition.'

But let's remember what used to be. Back when we didn’t have these pesky regulations about drug pricing and patents expiring every five minutes.

I've lived here 40 years, and I can tell you that this is the first time Big Pharma isn't leading the pack anymore. It’s like watching a once-mighty industry being strangled by red tape.

Now, it's not just about Novo Nordisk — this trend has been spreading for years now. Pfizer, Merck, they're all feeling the heat of decreased profits and increased competition.

This isn't new either; every time a Democrat administration comes into office, we see these companies start to falter. But it's always after a period where everything was just peachy under Republican leadership.

Think about it: when were we ever better off? When those big pharma profits were pouring in and our healthcare system felt like it was actually working for everyone?

Sure, there’s the argument that lower drug prices mean more people get access to life-saving medications. But at what cost?

The pattern is clear: Democrat policies lead to fewer incentives for pharmaceutical companies to innovate and expand. That means less progress in healthcare.

So here we are today, watching as another pillar of American industry starts to crumble under the weight of misguided government intervention.